Final - October 19, 2017

page 1 of 2

PURPOSE PRESIDER/PRESENTER(s)

Dr. Nancy Bennett (ACIP Chair)

Dr. Amanda Cohn (ACIP Executive Secretary; CDC)

8:30 Herpes Zoster Vaccine

Introduction

Review of GRADE (ZVL, HZ/su)

Cost effectiveness analysis

Considerations and proposed recommendations

Public comment

Dr. Edward Belongia (ACIP, WG Chair)

Ms. Angela Guo (CDC/NCIRD)

Dr. Lisa Prosser (University of Michigan)

Dr. Kathleen Dooling (CDC/NCIRD)

Vote Dr. Kathleen Dooling (CDC/NCIRD)

10:30

10:45 Hepatitis Vaccines 

Introduction

HEPLISAV-B 

Work Group considerations: HEPLISAV-B

Hepatitis A outbreaks

Dr. Arthur Reingold (ACIP, WG Chair)

Dr. Robert Janssen (Dynavax)

Dr. Noele Nelson (CDC/NCHHSTP)

Dr. Noele Nelson (CDC/NCHHSTP)

12:15

1:15 Influenza Vaccines

Introduction

Surveillance update

Coverage update

LAIV Efficacy/Effectiveness 2016-17 and strain selection update

Vaccine Safety Datalink Pregnancy Study

Work Group considerations: Influenza vaccines

Dr. Chip Walter (ACIP, WG Chair)

Ms. Lynnette Brammer (CDC/NCIRD)

Dr. Carla Black (CDC/NCIRD)

Dr. Raburn Mallory (MedImmune)

Dr. James Donahue (Marshfield)

Dr. Lisa Grohskopf (CDC/NCIRD)

2:30

2:45 Mumps

Introduction

Update on mumps epidemiology in the United States

GRADE: third dose of MMR vaccine

Considerations and proposed recommendations

Public comment

Vote

VFC vote

Dr. Kelly Moore (ACIP, WG Chair)

Dr. Mona Marin (CDC/NCIRD)

Dr. Mariel Marlow (CDC/NCIRD)

Dr. Mona Marin (CDC/NCIRD)

Dr. Mona Marin (CDC/NCIRD)

Dr. Jeanne Santoli (CDC/NCIRD)

4:30 Vaccine Safety: Shoulder Injury After Vaccination

Introduction

Data from HRSA Vaccine Injury Compensation Claims

Data from the Vaccine Adverse Event Reporting System

Communication and Education Campaign

Dr. Andrew Kroger (CDC/NCIRD)

Dr. Narayan Nair (HRSA)

Dr. Tom Shimabukuro (CDC/NCEZID)

Dr. Andrew Kroger (CDC/NCIRD)

5:00 Human Papillomavirus (HPV) Vaccines Update

Introduction

Update 

Dr. Peter Szilagyi ( ACIP, WG Chair)

Dr. Lauri Markowitz (CDC/NCIRD)

5:15

5:30 Adjourn

Information & 

Discussion

Public Comment

Information & 

Discussion

Information & 

Discussion

Information &

Discussion

Information & 

Discussion

Vote

VFC Vote

Break

Information

Wednesday, October 25

8:00 Welcome & Introductions

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

1600 Clifton Road, NE, Tom Harkin Global Communications Center, Kent "Oz" Nelson Auditorium

Atlanta, Georgia 30329 

October 25-26, 2017

AGENDA ITEM

Break

Vote

Lunch
Final - October 19, 2017

page 2 of 2

Information Dr. Nancy Messonnier (CDC/NCIRD); Ex Officio Members

8:30 Adult Immunization Schedule

Introduction

Proposed changes in the 2018 adult immunization schedule

Dr. Laura Riley (ACIP, WG Chair)

Vote Dr. David Kim (CDC/NCIRD)

9:00 Child/Adolescent Immunization Schedule 

Introduction

Proposed 2018 child and adolescent schedule revisions

Dr. José Romero (ACIP, WG Chair)

Vote Dr. Candice Robinson (CDC/NCIRD)

9:30 Japanese Encephalitis Vaccine

Introduction

JE among U.S. travelers

JE-VC post-marketing adverse event surveillance among U.S. military 

Adverse events following JE-VC reported to VAERS, 2012-2016

JE Vaccine Work Group summary and plans

Dr. Chip Walter (ACIP, WG Chair)

Dr. Susan Hills (CDC/NCEZID)

Dr. Christian Taucher (Valneva)

Dr. Susan Hills (CDC/NCEZID)

Dr. Susan Hills (CDC/NCEZID)

10:30 

10:50 Pneumococcal Vaccines 

Introduction

PCV13 impact on nasopharyngeal carriage among children and adults Information & 

Discussion

PCV13 impact on invasive pneumococcal disease: update from Active 

Progress of the research agenda to inform potential policy change for 

Dr. Arthur Reingold (ACIP, WG Chair)

Dr. Fernanda Lessa (CDC/NCIRD), Ms. Stephanie M. Thomas 

(Emory University School of Medicine)

Dr. Almea Matanock (CDC/NCIRD)

Dr. Tamara Pilishvili (CDC/NCIRD)

11:50 Anthrax Vaccines

Introduction

Preparedness/Operational concerns 

Anthrax vaccine (BioThrax®) new safety and reactionogenicity data 

Information on immunogenicity and reactogenicity given by 

Summary

Dr. David Stephens (ACIP, WG Chair)

Dr. William Bower (CDC/NCEZID)

Dr. Kate Hendricks (CDC/NCEZID)

Mr. Jarad Schiffer (CDC/NCIRD)

Dr. William Bower (CDC/NCEZID)

1:00 Evidence Based Recommendations Information Dr. Wendy Carr (CDC/NCIRD)

1:15 Respiratory Syncytial Virus (RSV) Vaccine Information Dr. Gayle Langley (CDC/NCIRD)

1:20 Vaccine Supply Information Dr. Jeanne Santoli (CDC/NCIRD)

1:25 Public Comment

1:40 Adjourn

Thursday, October 26

8:00 Agency Updates & Unfinished Business

CDC, CMS, DoD, DVA, FDA, HRSA, IHS, NIH, NVPO

Information & 

Discussion

Information & 

Discussion

Break

Acronyms

CDC Centers for Disease Control & Prevention

CMS Centers for Medicare and Medicaid Services 

DoD Department of Defense

DVA Department of Veterans Affairs

FDA Food and Drug Administration

GRADE Grading of Recommendations Assessment, Development and Evaluation

HRSA Health Resources and Services Administration

IHS Indian Health Service

JE-VC Vero cell culture-derived Japanese encephalitis vaccine 

NCHHSTP National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID] 

NCIRD National Center for Immunization & Respiratory Diseases [of CDC/OID] 

NCEZID National Center for Emerging and Zoonotic Diseases [of CDC/OID]

NVPO National Vaccine Program Office

PCV13 13-valent pneumococcal conjugate vaccine 

VFC Vaccines for Children

WG Work Group